Y. Salhi

Most-cited papers

1. Metachronous Peritoneal Metastases After Adjuvant Chemotherapy are Associated with Poor Outcome After Cytoreduction and HIPEC

   N. Sluiter, K. Rovers, Y. Salhi, S. Vlek +5 more

   2018Annals of Surgical Oncology27 citations Open access

   Semantic Scholar

   Save

2. Phytochemical Composition of Ziziphus lotus (L.) Lam and Its Impact on the Metabolic Syndrome: A Review

   Chaimae Alla, Amanat Ali, Afaf Mehiou, Y. Salhi +3 more

   2025Advances in pharmacological and pharmaceutical sciences11 citations Open access

   Semantic Scholar

   Save

3. Long-term survival following anti-PD-(L)1 monotherapy in advanced urothelial cancer and an assessment of potential prognostic clinical factors: a multicentre observational study

   C. Stockem, S. Einerhand, I. Rodriguez, Y. Salhi +19 more

   2024BJC Reports3 citations Open access

   Semantic Scholar

   Save

4. Lipid-Lowering and Hepatoprotective Effects of Basil-Enriched Soybean Oil (BEO) in High-Fat-Diet-Fed Mice

   Amani Tayebi, Mohammadine Moumou, Abdelhay Addous, Oussama Khibech +7 more

   2026Metabolites2 citations Open access

   Semantic Scholar

   Save

5. Novel molecular biomarkers to guide treatment-decision making in metastatic urothelial cancer - A patient cohort analysis

   D. Robbrecht, Y. Salhi, J. Martens, M. Aarts +9 more

   2025medRxiv2 citations Open access

   Semantic Scholar

   Save

6. Novel Molecular Biomarkers to Guide Treatment Decision-making in Metastatic Urothelial Cancer-A Patient Cohort Analysis.

   D. Robbrecht, Y. Salhi, J. Martens, M. Aarts +9 more

   2025European Urology Oncology2 citations Open access

   Semantic Scholar

   Save

7. Immunotherapy in Urothelial Cancer: Stop When Achieving a Response, Restart upon Disease Progression

   Y. Salhi, R. de Wit, D. Robbrecht

   2023Cancers2 citations Open access

   Semantic Scholar

   Save

8. The CHASIT study: sequential chemo-immunotherapy in patients with locally advanced urothelial cancer – a non-randomized phase II clinical trial

   V. Rutten, Y. Salhi, G. J. Robbrecht, R. de Wit +3 more

   2023BMC Cancer2 citations Open access

   Semantic Scholar

   Save

9. Longitudinal genome‐wide aneuploidy measurements in circulating cell‐free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancer

   Y. Salhi, Stavros Makrodimitris, S. van Wilpe, Iris B. A. W. Te Paske +11 more

   2026Molecular Oncology0 citations Open access

   Semantic Scholar

   Save

10. A0870 Sequential chemo-immunotherapy in patients with locally advanced urothelial cancer – interim results of the CHASIT study

    V. Rutten, Y. Salhi, G. V. van Leenders, A. G. van der Heijden +11 more

    2026European Urology0 citations

    Semantic Scholar

    Save

11. Genome-wide aneuploidy detected in circulating cell-free DNA of patients with metastatic urothelial cancer as a predictive biomarker of response to pembrolizumab.

    Y. Salhi, M. Rijnders, Pauline A. J. Mendelaar, Vania de Weert +10 more

    2023Journal of Clinical Oncology0 citations Open access

    Semantic Scholar

    Save

12. Rapid development of peritoneal metastases after adjuvant chemotherapy is associated with worse survival after cytoreduction and HIPEC

    N. Sluiter, Y. Salhi, S. Vlek, J. Tuynman

    20170 citations

    Semantic Scholar

    Save